• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Impinj Inc.
    $PI
    11/7/2025$200.00Neutral
    UBS
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    Impinj Inc.
    $PI
    10/8/2025$200.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    9/26/2025$18.00Neutral → Sell
    Goldman
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See Footnote Sylebra Capital Llc sold $12,827,818 worth of shares (78,062 units at $164.33) (SEC Form 4)

    4 - IMPINJ INC (0001114995) (Issuer)

    11/26/25 8:32:49 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    CHIEF FINANCIAL OFFICER Baker Cary gifted 1,000 shares, decreasing direct ownership by 1% to 80,479 units (SEC Form 4)

    4 - IMPINJ INC (0001114995) (Issuer)

    11/26/25 4:32:53 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    See Footnotes Sylebra Capital Llc sold $1,735,688 worth of shares (11,127 units at $155.99) (SEC Form 4)

    4 - IMPINJ INC (0001114995) (Issuer)

    11/24/25 7:18:53 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    Director Jennings Frank D bought $200,000 worth of shares (136,986 units at $1.46), increasing direct ownership by 796% to 154,189 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:59:46 PM ET
    $OCTO

    Director Caiano Nicola Paul was granted 2,960 shares and bought $500,000 worth of shares (342,466 units at $1.46), increasing direct ownership by 7,105% to 350,288 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:58:39 PM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Impinj with a new price target

    UBS initiated coverage of Impinj with a rating of Neutral and set a new price target of $200.00

    11/7/25 8:30:20 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    Wolfe Research initiated coverage on Apellis Pharmaceuticals

    Wolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform

    11/6/25 8:48:03 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    11/28/25 7:06:24 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 1-A filed by Dare Bioscience Inc.

    1-A - Dare Bioscience, Inc. (0001401914) (Filer)

    11/25/25 5:00:03 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cel-Sci Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - CEL SCI CORP (0000725363) (Filer)

    11/24/25 5:00:37 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

    FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studiesSeparately, FDA recently issued labeling comments, and labeling discussions have formally begun for the New Drug Application of tradipitant for the prevention of vomiting induced by motion (PDUFA target action date remains December 30, 2025)WASHINGTON, Nov. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), today announced the following updates regarding tradipitant for motion sickness: Partial Clinical

    11/28/25 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025

    NEW YORK, Nov. 25, 2025 /PRNewswire/ -- BIOLASE, the global leader in dental lasers, announced its participation in the 2025 Greater New York Dental Meeting (GNYDM), taking place November 28–December 3 in New York City. As part of the program, BIOLASE will host a featured lecture led by Philip Kang, DDS, focused on advancing laser solutions for periodontal and implant health. BIOLASE to Highlight YSGG Laser Innovations at GNYDM 2025 Dr. Kang will present "Advancing Laser Solutions for Periodontal and Implant Health" on Sunday, November 30 from 10:00 AM to 12:30 PM on the GNYDM

    11/25/25 9:00:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi's 2025 Global Healthcare Conference Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET Evercore 8th Annual Healthcare Conference  Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 30 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global bio

    11/25/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    SunPower Closes $37.5M Ambia Solar Acquisition

    OREM, Utah, Nov. 24, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (herein "SunPower," the "Company," or Nasdaq: "SPWR") a solar technology, services, and installation company, today announced that it has closed its $37.5 million strategic acquisition of Ambia Solar ("Ambia") to create the No. 5 U.S. residential solar company, based on Ohm Analytics rankings. SunPower CEO T.J. Rodgers said, "Due to our quick closing of the acquisition, we are raising our Q4'25 quarterly revenue estimate to $88 million. We still expect record operating income in Q4'25 and at least $2.0 million in operating income in Q1'26, the winter solar "down" quarter. In addition, and equally important, the acquisition brings

    11/24/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Signs LOI to Acquire Ambia Solar

    OREM, Utah, Nov. 11, 2025 (GLOBE NEWSWIRE) -- SunPower (herein "SunPower," the "Company" or Nasdaq: "SPWR") – a solar technology, services, and installation company – today announced that it has agreed to acquire Ambia Solar ("Ambia"), based in Lindon, Utah, just 1.7 miles from SunPower's HQ. Ambia is the No. 19 U.S. solar company by installed megawatts as reported by Ohm Analytics. The companies have signed a non-binding LOI for $37.5 million in equity. The transaction will close this quarter (Q4'25), subject to customary closing conditions. (The verb "will" in this press release should be interpreted as "will pursue the result stated in a definitive agreement scheduled for Q4'25 and act

    11/11/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Executes Major Sales Force Expansion Following Sunder Merger

    OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (NASDAQ:SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects to achieve record revenue of $83.3 million and record operating income of $3.5 million in Q4 2025. Eric Nielsen, SunPower's EVP of Sales said, "I am happy to report the integration of Sunder's salesforce into SunPower has been seamless and as a result, has enabled our team to continue to execute on plan without missing a beat. In addition, this deal has been well received across the industry — evidenced by the fact t

    10/30/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and DARE to RECLAIM™ Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Ea

    11/13/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T

    11/12/25 7:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

    11/6/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC